Home > Publications database > Genomic ALK alterations in primary and relapsed neuroblastoma. > print

001     271246
005     20240229154924.0
024 7 _ |a 10.1038/s41416-023-02208-y
|2 doi
024 7 _ |a pmid:36807339
|2 pmid
024 7 _ |a 0007-0920
|2 ISSN
024 7 _ |a 1532-1827
|2 ISSN
024 7 _ |a altmetric:142808455
|2 altmetric
037 _ _ |a DKFZ-2023-00378
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Rosswog, Carolina
|0 0000-0002-8855-6198
|b 0
245 _ _ |a Genomic ALK alterations in primary and relapsed neuroblastoma.
260 _ _ |a Edinburgh
|c 2023
|b Nature Publ. Group
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1686147161_31666
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a 2023 Apr;128(8):1559-1571
520 _ _ |a Genomic alterations of the anaplastic lymphoma kinase gene (ALK) occur recurrently in neuroblastoma, a pediatric malignancy of the sympathetic nervous system. However, information on their development over time has remained sparse.ALK alterations were assessed in neuroblastomas at diagnosis and/or relapse from a total of 943 patients, covering all stages of disease. Longitudinal information on diagnostic and relapsed samples from individual patients was available in 101 and 102 cases for mutation and amplification status, respectively.At diagnosis, ALK point mutations occurred in 10.5% of all cases, with highest frequencies in stage 4 patients <18 months. At relapse, ALK alteration frequency increased by 70%, both in high-risk and non-high-risk cases. The increase was most likely due to de novo mutations, frequently leading to R1275Q substitutions, which are sensitive to pharmacological ALK inhibition. By contrast, the frequency of ALK amplifications did not change over the course of the disease. ALK amplifications, but not mutations, were associated with poor patient outcome.The considerably increased frequency of ALK mutations at relapse and their high prevalence in young stage 4 patients suggest surveying the genomic ALK status regularly in these patient cohorts, and to evaluate ALK-targeted treatment also in intermediate-risk patients.
536 _ _ |a 312 - Funktionelle und strukturelle Genomforschung (POF4-312)
|0 G:(DE-HGF)POF4-312
|c POF4-312
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
700 1 _ |a Fassunke, Jana
|0 0000-0002-8391-5577
|b 1
700 1 _ |a Ernst, Angela
|b 2
700 1 _ |a Schömig-Markiefka, Birgid
|b 3
700 1 _ |a Merkelbach-Bruse, Sabine
|b 4
700 1 _ |a Bartenhagen, Christoph
|b 5
700 1 _ |a Cartolano, Maria
|b 6
700 1 _ |a Ackermann, Sandra
|0 0000-0002-5869-7344
|b 7
700 1 _ |a Theissen, Jessica
|b 8
700 1 _ |a Blattner-Johnson, Mirjam
|0 P:(DE-He78)261d2b84aded878003e6e35d18113831
|b 9
|u dkfz
700 1 _ |a Jones, Barbara
|0 P:(DE-He78)fae1bf941c5fd76cf5356ecfa1243cc4
|b 10
|u dkfz
700 1 _ |a Schramm, Kathrin
|0 P:(DE-He78)2f592d9d8339bee07cca3956b7472b61
|b 11
|u dkfz
700 1 _ |a Altmüller, Janine
|b 12
700 1 _ |a Nürnberg, Peter
|b 13
700 1 _ |a Ortmann, Monika
|b 14
700 1 _ |a Berthold, Frank
|b 15
700 1 _ |a Peifer, Martin
|0 0000-0002-5243-5503
|b 16
700 1 _ |a Büttner, Reinhard
|0 0000-0001-8806-4786
|b 17
700 1 _ |a Westermann, Frank
|b 18
700 1 _ |a Schulte, Johannes H
|b 19
700 1 _ |a Simon, Thorsten
|0 0000-0002-3425-8451
|b 20
700 1 _ |a Hero, Barbara
|b 21
700 1 _ |a Fischer, Matthias
|0 0000-0003-1363-1242
|b 22
773 _ _ |a 10.1038/s41416-023-02208-y
|0 PERI:(DE-600)2002452-6
|n 8
|p 1559-1571
|t British journal of cancer
|v 128
|y 2023
|x 0007-0920
909 C O |p VDB
|o oai:inrepo02.dkfz.de:271246
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 9
|6 P:(DE-He78)261d2b84aded878003e6e35d18113831
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 10
|6 P:(DE-He78)fae1bf941c5fd76cf5356ecfa1243cc4
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 11
|6 P:(DE-He78)2f592d9d8339bee07cca3956b7472b61
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-312
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Funktionelle und strukturelle Genomforschung
|x 0
914 1 _ |y 2023
915 _ _ |a DEAL Springer
|0 StatID:(DE-HGF)3002
|2 StatID
|d 2022-11-15
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2022-11-15
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2022-11-15
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2022-11-15
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-10-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-10-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2023-10-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-10-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2023-10-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-10-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2023-10-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2023-10-22
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b BRIT J CANCER : 2022
|d 2023-10-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2023-10-22
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2023-10-22
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b BRIT J CANCER : 2022
|d 2023-10-22
920 1 _ |0 I:(DE-He78)B360-20160331
|k B360
|l Pediatric Glioma
|x 0
920 1 _ |0 I:(DE-He78)HD01-20160331
|k HD01
|l DKTK HD zentral
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)B360-20160331
980 _ _ |a I:(DE-He78)HD01-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21